Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia
✍ Scribed by Erik Widerlöv; Ulf Andersson; Christer Bahr; Maj-Inger Nilsson
- Publisher
- Springer
- Year
- 1991
- Tongue
- English
- Weight
- 599 KB
- Volume
- 103
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Tardive dyskinesia (TD) occurs in approximately 20% of patients exposed to long‐term antipsychotic treatment and may be influenced by genetic predisposition, in addition to clinical risk factors. In this study, we implemented a two‐step approach to identify susceptibility genes for TD.
## Background: Chronically hospitalized geriatric inpatients with schizophrenia are at particular risk for both tardive dyskinesia (td) and cognitive impairment but have been insufficiently studied in this regard. similarly, the relationship between td and cognitive impairment has not be adequately